Aduro Biotech Inc. (NASDAQ:ADRO) shares shot up 3.2% on Friday . The stock traded as high as $15.70 and last traded at $15.70, with a volume of 185,659 shares changing hands. The stock had previously closed at $15.22.

ADRO has been the subject of a number of research reports. Canaccord Genuity reaffirmed a “buy” rating on shares of Aduro Biotech in a report on Tuesday, May 3rd. FBR & Co reaffirmed a “buy” rating and set a $34.00 target price (up from $30.00) on shares of Aduro Biotech in a report on Saturday, May 14th. Leerink Swann reaffirmed a “buy” rating and set a $48.00 target price on shares of Aduro Biotech in a report on Thursday, May 5th. Roth Capital reaffirmed a “buy” rating and set a $22.00 target price on shares of Aduro Biotech in a report on Monday, July 11th. Finally, Zacks Investment Research cut shares of Aduro Biotech from a “hold” rating to a “sell” rating in a research note on Monday, July 18th. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $22.00.

The company’s market capitalization is $1.02 billion. The firm has a 50-day moving average price of $13.46 and a 200 day moving average price of $13.24.

Aduro Biotech (NASDAQ:ADRO) last released its earnings results on Wednesday, August 3rd. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.21. The company earned $39 million during the quarter, compared to analyst estimates of $25.24 million. The company’s revenue was up 306.3% on a year-over-year basis. Equities research analysts expect that Aduro Biotech Inc. will post ($1.15) EPS for the current year.

In related news, insider Thomas W. Dubensky sold 25,000 shares of Aduro Biotech stock in a transaction that occurred on Thursday, August 11th. The shares were sold at an average price of $15.18, for a total value of $379,500.00. Following the completion of the sale, the insider now directly owns 12,500 shares in the company, valued at approximately $189,750. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

An institutional investor recently raised its position in Aduro Biotech stock. Jennison Associates LLC raised its stake in shares of Aduro Biotech Inc. (NASDAQ:ADRO) by 9.5% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 855,338 shares of the company’s stock after buying an additional 74,073 shares during the period. Jennison Associates LLC owned about 1.35% of Aduro Biotech worth $24,069,000 as of its most recent filing with the SEC.

Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.